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ABSTRACT: 
Medicinal plants have attracted increased 
attention because of their beneficial effects on human 
health. Many medicinal plants are used as traditional 
medicine in various countries for long time. A large 
number of secondary metabolites with various biological 
activities have been discovered from various medicinal 
plants and some bioactive substances derived from plants 
have diverse functional roles as secondary metabolites and 
these properties can be applied to the developments of 
novel pharmaceuticals. Leucas Urticifolia (family- 
Lamiaceae) is an annual herbaceous plant and has various 
activities. Chemical studies have underlined the presence 
of various classes of compounds, the main being 
triterpenes, diterpene, flavonoids and fatty acids. The 
extract of this plant as well as pure compounds isolated 
from this plant, have been demonstrated to posses multiple 
pharmacological activities. In this review, we have 
explored the phytochemistry and pharmacological activites 
of Leucas Urticifolia in order to collate existing 
information on this plant as well as highlight its multi-
activity properties as a medicinal agent.  
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The genus Leucas, belonging to the family 
Lamiaceae, comprises about 100 species. In the Indo-
Pakistani subcontinent, the genus is represented by 35 
species which are mostly herbs or under shrubs found in 
temperate or hilly regions (1). Leucas urticaefolia is an 
annual herb distributed in the Punjab, Baluchistan, Sindh 
and Rajputana desert of Pakistan. At Gomawal in 
Baluchistan, the plant is used as a cure for fever. It's local 
name in Gujerati is Kubo (2) and in Tilla Gogian of the 
Potohar region, it is known as Goma or Guldora. The 
decoction of the leaves and apical shoots with gur is used 
locally as an abortifacient up to 3 months of pregnancy. 
Infusions of the flowers are used in skin diseases. It is also 
used to treat piles. L. urticifolia is astringent, stimulant, 
haemostatic, anthelmintic and diuretic. The plant is also 
used for the treatment of diarrhea, dysentery, uterine 
haemorrhages, dropsy, gravel, cystitis, calculus, bronchial 
catarrh, skin diseases, fever and various types of mental 
disorders (1).  
 
DESCRIPTION: 
The plant is taxonomically classified as follow: 
Domain:  Eukaryota 
Kingdom:  Plantae 
Subkingdom: Angiospermae 
Phylum:  Eudicots 
Subphylum: core eudicots 
Order:  Lamiales 
Family:  Lamiaceae   
Subfamilia:  Lamioideae 
Genus:   Leucas 
Species:   Urticifolia 
Botanical name: Leucas urticifolia (Vahl) Benth. 
Synonyms: Phlomis urticifolia Vahl (basionym) 
Local name: Gujerati is Kubo, Goma or Guldora. 
 
DISTIBUTIONAL RANGE: 
Africa: Northern Africa: Egypt, Northeast Tropical Africa: 
Ethiopia; Sudan  
Asia-temperate: Arabian Peninsula: Oman; Saudi Arabia; 
Yemen 
Western Asia: Afghanistan; Iran  
Asia-tropical: Indian Subcontinent: India; Pakistan 
PHYTOCHEMISTRY: 
The aerial parts of plant are well investigated for chemical 
information (3). 
Triterpenes: Leucisterol, β-sitosterol, and ursolic acid (3),  
Diterpene: Momilactone-A (4) 
Flavonoids: Leufolins A, Leufolins B (5). 
Acids and esters: Urticic acid, Methoxybenzyl benzoate, 
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Leucisterol, Leufolins A and Leufolins B 
displayed inhibitory potential against butyrylcholinesterase. 
Butyrylcholinesterase (BChE, EC 3.1.1.8) inhibition may 
be an effective tool for the treatment of Alzheimer’s disease 
(AD) and related dementias. These inhibitors may act as 
potential leads in the discovery of clinically useful 
inhibitors for nervous system disorders, particularly by 
reducing memory deficiency in Alzheimer’s disease 
patients by potentiating and affecting the cholinergic 
transmission process (3,5). 
Cholinesterases are enzymes that share 
extensive sequence homology and distinct substrate 
specificity and inhibition sensitivity. Cholinesterases are 
potent target for the symptomatic treatment of Alzheimers 
disease and related dementia. It has been found that 
butyrylcholinesterase (BChE) inhibition is an effective tool 
for the treatment of AD and related dementias (6). It has 
been found that BChE is found in significantly higher 
quantities in Alzheimer plaques than in plaques of normal 
agerelated non-demented brains. It is general viewed as a 
back up for the homologus acetylcholinesterase and to act 
as a scavenger for anticholinesterase compounds (7). 
Butyrylcholinesterase is involved three different enzymatic 
activities in its structure like its sister enzyme, 
acetylcholinesterase: esterase, aryl acylamidase and pepti-
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dase (or protease). Whereas the clear role of 
acetylcholinesterase in cholinergic neurotransmission is 
well defined, the real physiological function of butyrylcho-
linesterase is still unknown. Both enzymes have similar 
molecular forms with different tissue distribution. Esteratic 
activity of butyrylcholinesterase becomes more important 
in scavenging of organophosphate and carbamate inhibitors 
before they reach to acetylcholinesterase; in regulating 
cholinergic transmission in the absence of 
acetylcholinesterase and in inactivation of some drugs such 
as cocaine aspirin, amitriptyline or in activation of others 
such as bambuterol, heroin. It is suggested that aryl 
acylamidase activity plays a role in crosstalking between 
seratonergic and cholinergic neurotransmission systems. In 
addition, peptidase activity of butyrylcholinesterase has a 
function in the development and progression of Alzheimer 
disease due to cause the production of β-amyloid protein 
and to help its diffusion to β-amyloid plaques. 
Animal cholinesterases are widespread enzymes 
present in cholinergic and noncholinergic tissues as well as 
in their plasma and other body fluids (8-11). They are 
divided into two classes according to differing in their 
subtrate specificity, behaviour in excess substrate and 
susceptibility to inhibitors: acetylcholinesterase or “true 
cholinesterase” (AChE; acetylcholine acetylhydrolase, E.C. 
3.1.1.7) and butyrylcholinesterase (BChE; acylcholine 
acylhydrolase, E.C. 3.1.1.8). BChE is also known as 
pseudocholinesterase, non-specific cholinesterase or 
simply cholinesterase. AChE hydrolyzes acetylcholine 
faster than other cholinesters and is much less active on 
butyrylcholine. On the contrary, BChE pereferentially acts 
on butyrylcholine, but also hydrolyzes acetylcholine 
(10,12). The inhibition of AChE by excess substrate is one 
of the key features that distinguishes it from BChE. BChE 
exhibits the substrate activation in excess substrate (13,14). 
Their tissue-specific distribution is also different from each 
other: AChE is known to be abundant in brain, muscle and 
erythrocyte membrane, whereas BChE has higher activity 
in liver, intestine, heart, kidney and lung (15,16). Many 
species such as human, horse, mice exhibit high BChE 
activity in their plasma, while rat has higher AChE activity 
than BChE in its plasma (10,16,17).  
AChE and BChE share 65% amino acid 
sequence homology and have similar molecular forms and 
active center structure despite being products of different 
genes on human choromosomes 7(specifically 7q22) and 
3(specifically 3q26), respectively (18). The main function 
of AChE is rapid hydrolysis of the neurotransmitter 
acetylcholine at cholinergic synapses, and it is one of the 
fastest enzyme known (19). But individuals whose BChE is 
absent does not correlate with any physiological 
abnormality. Its importance as a detoxification enzyme is 
growing interest in recent years. BChE is of 
pharmacological and toxicological importance, because it 
hydrolyzes ester-containing drugs and scavenges 
cholinesterase inhibitors including potent 
organophosphporus nerve agents before they reach their 
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